179 related articles for article (PubMed ID: 36133439)
21. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
22. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
23. Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation.
Guan R; Zou J; Mei J; Deng M; Guo R
BMC Cancer; 2022 Jul; 22(1):830. PubMed ID: 35907846
[TBL] [Abstract][Full Text] [Related]
24. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
Fang G; Zhang Q; Fan J; Li H; Ding Z; Fu J; Wu Y; Zeng Y; Liu J
BMC Cancer; 2022 Sep; 22(1):999. PubMed ID: 36127654
[TBL] [Abstract][Full Text] [Related]
25. Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma.
Li MM; Tang YQ; Gong YF; Cheng W; Li HL; Kong FE; Zhu WJ; Liu SS; Huang L; Guan XY; Ma NF; Liu M
BMC Cancer; 2019 Aug; 19(1):851. PubMed ID: 31462277
[TBL] [Abstract][Full Text] [Related]
26. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.
Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J
Front Immunol; 2022; 13():994259. PubMed ID: 36341373
[TBL] [Abstract][Full Text] [Related]
27. m
Qu X; Zhang L; Li S; Li T; Zhao X; Wang N; Shi Y
Oxid Med Cell Longev; 2022; 2022():8301888. PubMed ID: 36246403
[TBL] [Abstract][Full Text] [Related]
28. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma.
Shi Y; Wang J; Huang G; Zhu J; Jian H; Xia G; Wei Q; Li Y; Yu H
Hepatol Int; 2022 Aug; 16(4):906-917. PubMed ID: 35699863
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
30. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
[TBL] [Abstract][Full Text] [Related]
31. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients.
Lv W; Yao Q
Dis Markers; 2022; 2022():9428660. PubMed ID: 35069936
[TBL] [Abstract][Full Text] [Related]
32. A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration.
Long M; Zhou Z; Wei X; Lin Q; Qiu M; Zhou Y; Chen P; Jiang Y; Wen Q; Liu Y; Li R; Zhou X; Yu H
Front Immunol; 2022; 13():1023349. PubMed ID: 36353638
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.
Wang J; Han K; Zhang C; Chen X; Li Y; Zhu L; Luo T
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988674
[TBL] [Abstract][Full Text] [Related]
34. Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis.
Zhen Z; Shen Z; Hu Y; Sun P
Aging (Albany NY); 2021 Jul; 13(13):17707-17733. PubMed ID: 34252885
[TBL] [Abstract][Full Text] [Related]
35. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
37. Protective effect of tertiary lymphoid structures against hepatocellular carcinoma: New findings from a genetic perspective.
Jia W; Yao Q; Wang Y; Mao Z; Zhang T; Li J; Nie Y; Lei X; Shi W; Song W
Front Immunol; 2022; 13():1007426. PubMed ID: 36189217
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
39. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
40. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
